Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Early Diabetic Kidney Disease
NCT03173963Phase 3Withdrawn
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- May 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic kidney disease (DKD) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Change in cortical interstitial fractional volume [Vv(Int/cortex)] at 3 years. Planned start May 2017; status: withdrawn.
02
Drugs
empagliflozin
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT03173963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173963.